Industry

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results … [Read more…]

NeuraLight Reveals the World-Class Scientific Leaders Helping to Advance Its Transformation of Disease Progression Measurement in Neurology

Precision biomarker company’s Scientific Advisory Board includes multiple Nobel Prize winners and the creators of current gold standard in Parkinson’s disease progression CAMBRIDGE, Mass., AUSTIN, Texas & TEL AVIV, Israel–(BUSINESS WIRE)–NeuraLight, the leader in developing precision biomarkers for neurological disease, today announced that Prof. Thomas Südhof, a Nobel Prize-winning neuroscientist and one of the world’s … [Read more…]

SBC Medical Group Holdings: Announcement of Final Results of Tender Offer for Waqoo, Inc. Shares

Strategic acquisition strengthens SBC’s comprehensive service offerings and R&D capabilities TOKYO–(BUSINESS WIRE)–#Healthcare–SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services for medical organizations, today announced the final results of its tender offer for common shares of Waqoo, Inc. (TOKYO:4937) (the “Tender Offer”), a … [Read more…]

Non-Opioid Therapeutics Market Insights, Shares and Growth Outlook 2025-2032: Rising Integration of Non-Opioid Options in Multimodal Pain Management Protocols – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Non-Opioid Therapeutics Market – Global Forecast 2025-2032” has been added to ResearchAndMarkets.com’s offering. This market research report focuses on the evolving landscape of the Non-Opioid Therapeutics Market. This sector has grown from USD 40.77 billion in 2024 to USD 43.78 billion in 2025, with projections suggesting a CAGR of 7.68% leading to a … [Read more…]

Alcohol Use Disorder: Global Market Analysis, Trends and Competition Outlook 2025-2032 – Rising Adoption of AI-Driven Predictive Analytics in Mobile Health Apps – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Alcohol Use Disorder Market – Global Forecast 2025-2032” report has been added to ResearchAndMarkets.com’s offering. The Alcohol Use Disorder Market is rapidly evolving as digital advancements, collaborative care models, and shifting regulatory dynamics converge to transform patient management and industry strategies. Comprehensive market analysis equips decision-makers with actionable insights into commercial opportunities, leading … [Read more…]

Hand Soap Market Intelligence Report: Trends, Forecast and Competitive Analysis to 2031 Featuring Profiles of Reckitt Benckiser, P&G, Unilever, Lion, Medline, and Chattem Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hand Soap Market Report: Trends, Forecast and Competitive Analysis to 2031” has been added to ResearchAndMarkets.com’s offering. The global hand soap market is expected to grow with a CAGR of 6.7% from 2025 to 2031. Major drivers for this market include increasing awareness about hand hygiene globally, rising demand for natural organic hand … [Read more…]

Haleon Recognized by Fast Company as a 2025 Brands That Matter Honoree

Haleon earns distinction in the Family of Brands category for building enduring trust and consumer connection Award highlights Haleon’s leadership in purposeful innovation and consumer impact WARREN, N.J.–(BUSINESS WIRE)–Haleon, a global leader in consumer health, today announced it has been honored in Fast Company’s 2025 Brands That Matter list in the Family of Brands category, … [Read more…]

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, to receive a positive recommendation for marketing authorization in Europe. For patients whose disease does not respond to BCG, there are currently no authorized treatment options; the primary option is surgical removal … [Read more…]

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to Genmab’s EBITDA by end of 2029   COPENHAGEN, Denmark–(BUSINESS WIRE)–Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by … [Read more…]

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Phase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the treatment of uncomplicated urogenital gonorrhea. Positive study results are a significant milestone in the development of a first-in-class single-dose, oral antibiotic against gonorrhea, including infections caused by drug-resistant Neisseria gonorrhoeae, an urgent public health threat and high-priority … [Read more…]